Viatris (VTRS) Cash from Investing Activities Growth (1y) (2020 - 2026)
Viatris (VTRS) Cash from Investing Activities Growth (1y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.92 Bn | 42.96 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.19 Bn | 39.53 Bn | 2.15 Bn | -308.05% |
| 3 | Zoetis | 31.74 Bn | 30.06 Bn | 1.05 Bn | -41.51% |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.87 Bn | 5.10 Bn | -139.86% |
| 5 | United Therapeutics | 22.22 Bn | 19.56 Bn | 683.80 Mn | 129.18% |
| 6 | Viatris | 18.71 Bn | 17.83 Bn | 1.46 Bn | 1.71% |
| 7 | Neurocrine Biosciences | 15.55 Bn | 15.16 Bn | 935.80 Mn | -366.90% |
| 8 | Elanco Animal Health | 11.80 Bn | 11.27 Bn | 798.00 Mn | -96.43% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | Alkermes | 8.12 Bn | 7.47 Bn | 397.90 Mn | 91.75% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.71% |
| Mar 31, 2026 | 526.11% |
| Dec 31, 2025 | -25.19% |
| Sep 30, 2025 | -105.66% |
| Jun 30, 2025 | -113.97% |
| Mar 31, 2025 | 57.81% |
| Dec 31, 2024 | -731.84% |
| Sep 30, 2024 | 3,283.79% |
| Jun 30, 2024 | 532.95% |
| Mar 31, 2024 | 79.41% |
| Dec 31, 2023 | -98.46% |
| Sep 30, 2023 | 52.26% |
| Jun 30, 2023 | -5.72% |
| Mar 31, 2023 | -1,020.33% |
| Dec 31, 2022 | 893.29% |
| Sep 30, 2022 | 2.71% |
| Jun 30, 2022 | -388.69% |
| Mar 31, 2022 | -128.31% |
| Dec 31, 2021 | -882.51% |
| Mar 31, 2021 | 262.29% |